Mizuho Securities Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186
November 10, 2015 9:51 AM ESTPiper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More
Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
November 10, 2015 8:42 AM ESTLeerink Partners maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $187.00 (from $220.00), following the company's 3Q earnings report. JAZZs update included a modest topline miss driven by slower patient volume growth as the company experienced delays in Xyrem refills.
Analyst Jason... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
November 9, 2015 4:10 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More
